This includes improvement in endothelial dysfunction through effects on Kruppel-like factor 2 (KLF-2) and increased nitric oxide (NO) bioavailability through modulation of endothelial NO synthase and enhancing eNOS mRNA stability (41–43). The gene discussed is KLF2; the disease is endothelial dysfunction.